Posts by: Patricia Inacio, PhD

Patricia Inacio, PhD

Patricia holds a Ph.D. in Cell Biology from University Nova de Lisboa, and has served as an author on several research projects and fellowships, as well as major grant applications for European Agencies. She has also served as a PhD student research assistant at the Department of Microbiology & Immunology, Columbia University, New York.

January 21, 2020January 21, 2020

Scientists Identify Compounds That Can Protect Brain Mitochondria From Damage Associated With Alzheimer’s

News

A new screening assay has identified small molecules capable of protecting brain mitochondria from stress conditions that commonly occur in Alzheimer’s and other neurodegenerative diseases. These preclinical results in ... Read more

January 20, 2020January 20, 2020

Protein Known to Ovarian Cancer Appears to Play Role in Alzheimer’s, Study Suggests

News

A protein involved in ovarian cancer, known as OCIAD1, contributes to the neurodegeneration seen in Alzheimer’s disease, and may be a more fitting treatment target than beta-amyloid, a protein ... Read more

January 13, 2020January 13, 2020

Vaccine Combination Against Amyloid-Beta and Tau Proteins Shows Promise in Mouse Model of Alzheimer’s

News

Immunization with two experimental vaccines targeting the toxic forms of amyloid-beta and tau protein — two hallmarks of Alzheimer’s disease — triggered an immune response that reduced the levels of ... Read more

December 18, 2019December 18, 2019

Troriluzole Shows Potential to Treat Moderate Alzheimer’s in Phase 2/3 Trial, Monitoring Board Rules

News

Troriluzole, an investigational oral therapy by Biohaven, shows a potential to improve cognition and lessen brain volume loss, a sign of Alzheimer’s disease progression, a board reviewing the ongoing ... Read more

December 3, 2019December 3, 2019

Trials into Possible Treatment for Agitation in Alzheimer’s Patients to Continue, Avanir Says

News

A potential oral treatment for agitation due to Alzheimer’s dementia, AVP-786, will continue in advanced clinical testing after a fuller analysis of data from two completed Phase 3 trials, Avanir Pharmaceuticals said. ... Read more

November 6, 2019November 6, 2019

$15M Investment Helps Secure Funding for Phase 2 Trial of T3D-959 for Alzheimer’s

News

T3D Therapeutics has secured the needed funding to move forward with its Phase 2 trial testing T3D-959 as a potential treatment for people with mild-to-moderate Alzheimer’s disease. The total ... Read more

November 5, 2019November 5, 2019

Seaweed-based Therapy Approved in China for Mild to Moderate Alzheimer’s, 1st New Treatment in 16 Years

News

Oligomannate (GV-971), a compound derived from marine brown algae that promotes a healthy gut microbiome, is now conditionally approved in China to treat mild to moderate Alzheimer’s disease (AD), ... Read more

November 1, 2019November 1, 2019

INmune Bio’s XPro1595 May Help Lower Neuroinflammation Triggered by High Fat and Sugar Diet, Mouse Study Suggests

News

Treatment with INmune Bio‘s lead candidate XPro1595 can help decrease neuroinflammation and amyloid beta accumulation triggered by a diet high in sugar and fats, according to results from a ... Read more

October 25, 2019October 25, 2019

CareBand Tracking Bracelet Wins NIH Award, May Detect Agitation in Alzheimer’s, Related Dementias

News

CareBand’s tracking bracelet, which pairs GPS technology to track movement and activity in real time, has been granted the National Institutes of Health (NIH) Phase 1 Small Business Innovation ... Read more

October 16, 2019October 16, 2019

Oral Anticoagulant Dabigatran Prevented Memory Loss in Mouse Model of Alzheimer’s, Study Shows

News

Oral treatment over one year with an approved blood thinner called dabigatran prevented memory loss, preserved blood circulation in the brain and reduced the amount of senile plaques in ... Read more

Pin It on Pinterest